YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Pharmacokinetic Interactions of Diltiazem and Acebutolol

딜티아젬과 아세부토롤의 약물상호작용

  • Published : 2001.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Acebutolol is almost absorbed after oral administration, but its bioavailability is reduced because of considerable first-pass metabolism through the gastrointestinal tract and liver. The purpose of this study was to report the pharmacokinetic changes of acebutolol (15 mg/kg,oral) and its main metabolite, diacetolol in rabbits pretreated (15 mg/kg, oral) and coadministered (15 mg/kg, S. C., bid for 3 days) with diltiazem. The plasma concentration and area under the plasma concentration-time curves (AUC) of acebutolol and diacetolol were significantly increased in rabbits pretreated and coadministered with diltazem. The elimination rate constant ( $K_{el}$ ) and total body clearances (CL $_{t}$) of acebutolol and diacetolol were significantly decreased and half-life of those were significantly prolonged in the rabbit. Metabolite percentage rate of diacetolol to the plasma concentration of total acebutolol in rabbits pretreated and coadministered with diltiazem were significantly decreased. The results suggest that the dosage of acebutolol should be adjusted when the drug would be administered chronically with diltiazem in a clinical situation.n.

Keywords

References

  1. Am. J. Med. v.64 no.1005 Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker acebutolod and diuretics in essential hypertension Alhenz-Gelas, F.;Plouin, P. F.;Ducrocq, M. B.;Corvol, P. E.;Menard, J.
  2. Br. J. Clin. Pharmcol. v.6 no.351 Acebutolol in hypertension a double blind trial against placebo Martin, M. A.;Phillips, C. A.;Smith, A. J.
  3. J. Int. Med. Res. v.7 no.201 Multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice Baker, P. G.;Goulton, J. A.
  4. Br. J. Clin. Pharmacol. v.9 no.215 Pharmacokinetics of acebutolol after intravenous bolus administration Roux, A.;Flouvat, B.;Chau, N. P.;Letac, B.;Lucsko, B.
  5. Clin. Pharmacol. Ther. v.24 no.5 Food, splanchnic blood flow and bioavailability of drugs subject to first pass metabolism Mclean, A. J.;Mcnamara, R. J.;Souich, P. D.;Gibaldi, M.;Lalka, D.
  6. Eur. J. Pharmacol. v.80 no.47 Pharmacological properties of diacetolol, a major metabolite of acebutolol Basil, J.;Jordan, R.
  7. Br. J. Clin. Pharmacol. v.9 no.215 Pharmacokinetics of acebutolol after intravenous bolus administration Roux, A.;Flouvat, B.;Chau, N. P.;Letac, B.;Luckso, M.
  8. Eur. J. Clin. Pharmacol. v.31 no.643 Pharmacokinetics and bioavailability of diacetolol, the main matabolite of acebutolol Flouvat, B.;Roux, A.;Chau, N. P.
  9. J. Pharm. Phatmacol. v.31 no.643 Elimination of drugs by active intestinal transport George, C. F.;Gruchy, B. S.
  10. Biopharm. Drug Dispos. v.2 no.103 The Pharmacokinetics of acebutolol in man, following the oral administration of acebutolol as a single dose and during and after repeated oral dosing Gulaid, A. A.;James, I. M.;Kaye, C. M.
  11. J. Pharm. Pharmacol. v.33 no.386 Preliminary observations on the excretion of acebutolol and its acetyl matabolite in the urine and feces of man Gabriel, R.;Kaye, C. M.;Sankey, M. G.
  12. Biopharm. Drug Dispos. v.3 no.47 The effect of hydralazine on the pharm-acokinetics of three different beta-adrenoceptor antagonists: metoprololol, nadolol, and acebutolol Jack, D. B.;Kendall, M. J.;Dean, S.;Laugher, S. J.;Zaman, R.
  13. J. Cardio. Pharm. v.3 no.403 Sulfinpyrazone dose not alter the pharmacokinetics of acebutolol Patard, O.;Mier, F.;Carbon, C.;Roux, A.;Flouvat, B.
  14. Biopharm. Drug Dispos. v.5 no.91 The effect of food and alcohol on the pharm-acokinestics of acebutolol and its metabolite, diacetolol Zaman, B.;Wilkins, M. R.;Kendall, M. J.;Jack, D. B.
  15. J. Chromatogr. v.230 no.438 High performance liquid chromatography assay of acebutolol and its metabolites in plasma and urine Buskin, J. N.;Upton, R. A.;Jones, R.;Williams, R. L.
  16. Computer Programs in Biomedicine v.16 no.203 LAGRAN program for area and moments in pharmacokinetic analysis Rocci, M. L.;Jusko, W. J.
  17. Cardiovasc. Drugs Ther. v.10 no.Suppl3,869 Pharmacological aspects of calcium channel blockers Scholz, H.
  18. Am. J. Kidney Dis. v.16 no.Suppl 1,10 Effects of calcium antagonists on renal hemodynamics Epstein, M.
  19. Clin. Pharmacol. Ther. v.40 no.140 Diltiazem treatment impairs hepatic drug oxidation of antipyrine Carrum, G.;Eagam, J. M.;Abemethy, D. R.
  20. Clin. Pharmacol. Ther. v.44 no.29 Effect of calcium channel blockers on theophylline disposition Susan, M. S.;John, A. P.;Timothy, H. S.
  21. Clin. Pharmacol. Ther. v.46 no.668 The effect of diltiazem on the disposition of encainide and its active metabolites Kazierad, D. J.;Richard, L. L.;Michael, B.
  22. Clin. Pharmacol. Ther. v.38 no.667 Effects of verapamil, diltiazen, and nifedipine on plasma levels and renal excretion of digitoxin Kuhlmann, J.
  23. Clin. Pharmcol. Ther. v.46 no.469 Synergistic adverse hemodynamic interation between oral verapamil and propranolol Carruthers, G.;David, J. F.;David, G. B.
  24. Clin. Pharmacol. Ther. v.37 no.150 Effects of nifedipine and diltiazem on plasma levels and renal excretion of beta-acetyldigoxin Kuhlmann, J.
  25. Kor. J. Clin. Pharm. v.3 no.139 Pharmacokinetics of phenytoin in rabbits pretreated with diltiazem Park, J. M.;Lee, J. H.;Choi, J. S.;Burm, J. P.